Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Transcenta Holding Limited ( (HK:6628) ) has provided an announcement.
Transcenta Holding Limited announced its audited consolidated financial results for the year ending December 31, 2024, revealing a significant decrease in revenue and other income, primarily due to a reduction in CDMO services and interest income. Despite these declines, the company managed to reduce its overall loss and comprehensive expenses by reprioritizing its research and development investments and cutting administrative costs, which may positively impact its future financial stability and operational focus.
More about Transcenta Holding Limited
Transcenta Holding Limited is a biotechnology company focused on the development and manufacturing of innovative therapeutics. The company operates in the biopharmaceutical industry, providing Contract Development and Manufacturing Organization (CDMO) services, which are integral to its operations.
YTD Price Performance: 188.89%
Average Trading Volume: 914,051
Technical Sentiment Signal: Hold
Current Market Cap: HK$775.9M
Find detailed analytics on 6628 stock on TipRanks’ Stock Analysis page.